Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan1, M. Özgüroğlu2, D. Daniel3, A. Villegas4, D. Vicente5, S. Murakami6, R. Hui7, C. Faivre-Finn8, L. Paz-Ares9, Y. L. Wu11, H. Mann12, P. A. Dennis13, & S. J. Antonia14

1Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands; 2Istanbul University—Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey; 3Tennessee Oncology, Chattanooga; 4Sarah Cannon Research Institute, Nashville; 5Cancer Specialists of North Florida, Jacksonville, USA; 6Hospital Universitario Virgen Macarena, Seville, Spain; 7Kanagawa Cancer Center, Yokohama, Japan; 8Westmead Hospital and the University of Sydney, Sydney, Australia; 9The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK; 10Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, Spain; 11Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; 12AstraZeneca, Cambridge, UK; 13AstraZeneca, Gaithersburg; 14H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA

Available online 2 March 2022

Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.

Materials and methods: Patients with unresectable, stage III NSCLC and no disease progression after ≥2 cycles of platinum-based, concurrent CRT were randomized 2:1 to receive durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months) or placebo, 1-42 days after CRT. The primary endpoints were progression-free survival (PFS; assessed by blinded independent central review according to RECIST version 1.1) and overall survival (OS). Treatment effects within subgroups were estimated by hazard ratios (HRs) from unstratified Cox proportional hazards models.

Results: Of 713 randomized patients, 287 (40%) had stage IIIA-N2 disease. Baseline characteristics were similar between patients with and without stage IIIA-N2 NSCLC. With a median follow-up of 14.5 months (range: 0.2-29.9 months), PFS was improved with durvalumab versus placebo in both patients with [HR = 0.46; 95% confidence interval (CI), 0.33-0.65] and without [HR = 0.62; 95% CI 0.48-0.80] stage IIIA-N2 disease. Similarly, with a median follow-up of 25.2 months (range: 0.2-43.1 months), OS was improved with durvalumab versus placebo in patients with [HR = 0.56; 95% CI 0.39-0.79] or without [HR = 0.78; 95% CI 0.57-1.06] stage IIIA-N2 disease. Durvalumab had a manageable safety profile irrespective of stage IIIA-N2 status.

Conclusions: Consistent with the intent-to-treat population, treatment benefits with durvalumab were confirmed in patients with stage IIIA-N2, unresectable NSCLC. Prospective studies are needed to determine the optimal treatment approach for patients who are deemed operable.

Key words: immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy

INTRODUCTION

The results of the phase III PACIFIC trial demonstrated that durvalumab monotherapy [for up to 12 months] improved survival in patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following platinum-based, concurrent chemoradiotherapy (cCRT). Durvalumab [an anti-programmed cell death-ligand 1 (PD-L1) antibody] significantly improved progression-free survival [PFS: stratified hazard ratio (HR) = 0.52; 95% confidence interval (CI) 0.42-0.65; \( P < 0.0001 \)] and overall survival (OS: stratified HR = 0.68; 95% CI 0.53-0.87; \( P = 0.00251 \)) versus placebo in the intent-to-treat (ITT) population.\(^1\) Furthermore, durvalumab exhibited a manageable safety profile and did not detrimentally impact patient-reported outcomes compared with placebo.\(^2\) Based on these findings, the ‘PACIFIC regimen’...
(consolidation durvalumab after platinum-based CRT) has been established as the new standard of care in this setting. Stage IIIA-N2 NSCLC represents a heterogeneous disease group, with some patients being potentially eligible for thoracic surgery. Before the approval of durvalumab, the recommended therapeutic approach for patients with stage IIIA-N2 disease comprised multimodality treatment with chemotherapy, radiotherapy, and (in patients deemed operable) a surgical resection. Given the clinically meaningful improvements demonstrated with the PACIFIC regimen across a wide population of patients with unresectable, stage III NSCLC, the potential utility of immunotherapy in this setting warrants further evaluation in patients with stage IIIA-N2 disease who are deemed operable. Here we report a post hoc, exploratory analysis of clinical outcomes with durvalumab in patients from the PACIFIC trial with or without stage IIIA-N2, unresectable NSCLC.

MATERIALS AND METHODS

Study design

The eligibility criteria and study design for PACIFIC (NCT02125461), a randomized, double-blind, international, multicenter trial, have been described previously. Briefly, eligible patients had histologically or cytologically documented stage III, unresectable NSCLC, (according to the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology, version 7) and had not progressed after at least two cycles of platinum-based, cCRT. Enrolled patients were randomized in a 2:1 ratio to receive either durvalumab (10 mg/kg bodyweight; AstraZeneca, Gaithersburg, MD) or placebo intravenously once every 2 weeks for 12 months, or until confirmed disease progression, initiation of an alternative anticancer therapy, development of unacceptable toxicities, or withdrawal of consent. All patients provided written informed consent for participation in the trial, which was approved by relevant ethics committees and carried out in accordance with the International Conference on Harmonization Guidelines on Good Clinical Practice and the Declaration of Helsinki.

Endpoints and assessments

The primary endpoints were PFS [by blinded independent central review as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1] and OS. Secondary efficacy endpoints included time to death or distant metastasis (TTDM), objective response rate (ORR), and safety (graded as per Common Terminology Criteria for Adverse Events version 4.03).

A post hoc, exploratory analysis of these endpoints was conducted in subgroups comprising patients with or without stage IIIA-N2 NSCLC; the subgroup without stage IIIA-N2 disease included patients with all other stages [i.e. stage IIIA non-N2 (T3N1, T4N0, and T4N1) and stage IIIB].

Statistical analyses

Analysis of RECIST-assessed endpoints (PFS, TTDM, and ORR) was based on the data cut-off (DCO) used for the primary analysis of PFS (13 February 2017). OS and safety were analyzed based on the DCO used for the primary analysis of OS (22 March 2018).

Treatment effects (HRs) for time-to-event endpoints were estimated using unstratified Cox proportional hazards models, with treatment being the only covariate. Medians and associated 95% CIs were estimated with the Kaplan—Meier method. Adverse events (AEs), all-cause pneumonitis (i.e. pneumonitis/radiation pneumonitis), and ORR were summarized descriptively. All data were summarized based on the ITT population except for safety data, which were summarized based on the as-treated population.

RESULTS

Of the 713 randomized patients, 287 (40.3%) had stage IIIA-N2 disease; 197/476 (41.4%) and 90/237 (38.0%) in the durvalumab and placebo arms, respectively. Baseline characteristics were broadly similar between patients with and without stage IIIA-N2 NSCLC (Table 1). Proportionally more patients with (versus those without) stage IIIA-N2 NSCLC were aged ≥65 years in both study arms and proportionally fewer received pre-CRT induction chemotherapy. Approximately one-quarter of patients were randomized to study treatment within 1-14 days of completing radiotherapy, regardless of stage IIIA-N2 status [67/287 (23.3%) patients with and 115/426 (27.0%) patients without stage IIIA-N2 NSCLC]. Within the placebo arm, proportionally more patients with (versus those without) stage IIIA-N2 NSCLC were male [67/90 (76.7%) versus 97/147 (66.0%)] and proportionally fewer had an objective tumor response during prior cCRT [34/90 (37.8%) versus 85/147 (57.8%)]. Consistent with the ITT population, proportionally more patients completed the full 12-month treatment course in the durvalumab arm compared with the placebo arm, irrespective of stage IIIA-N2 status [stage IIIA-N2: 98/195 (50.3%) versus 27/89 (30.3%); all others: 134/278 (48.2%) versus 55/147 (37.4%)] (Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2022.100410).

At the DCO for its primary analysis, PFS favored durvalumab compared with placebo in both patients with (HR = 0.46; 95% CI 0.33-0.65) and without (HR = 0.62; 95% CI 0.48-0.80) stage IIIA-N2 disease [Figure 1; DCO: 13 February 2017, median follow-up: 14.5 months (range: 0.2-29.9 months)]. Likewise, at the DCO for its primary analysis, OS favored durvalumab versus placebo in patients with (HR = 0.56; 95% CI 0.39-0.79) or without (HR = 0.78; 95% CI 0.57-1.06) stage IIIA-N2 disease [Figure 2; DCO: 22 March 2018, median follow-up: 25.2 months (range: 0.2-43.1 months)]. In addition, TTDM and ORR favored durvalumab versus placebo in both patients with and without stage IIIA-N2 disease (Table 2).

The incidences of any-grade, grade 3/4, and serious AEs were broadly similar between patients with and without stage IIIA-N2 disease irrespective of study treatment.
Table 1. Baseline demographics, disease characteristics, and prior anticancer therapy in patients with or without stage IIIA-N2 NSCLC

|                                | Patients with stage IIIA-N2 NSCLC | Patients without stage IIIA-N2 NSCLC |
|--------------------------------|-----------------------------------|-------------------------------------|
|                                | Durvalumab (n = 197)              | Placebo (n = 90)                     |
|                                |                                   |                                     |
| Median age (range), years      | 65.0 (33-83)                      | 65.0 (23-90)                        |
| Age ≥65 years, n (%)           | 112 (56.9)                        | 46 (51.1)                           |
| Male, n (%)                    | 132 (67.0)                        | 67 (76.7)                           |
| Race, n (%)                    |                                    |                                     |
| White                          | 140 (71.1)                        | 59 (65.6)                           |
| Black or African American      | 4 (2.0)                           | 1 (1.1)                             |
| Asian                          | 50 (25.4)                         | 29 (32.2)                           |
| Other/missing                  | 3 (1.5)                           | 1 (1.1)                             |
| Median weight (range), kg      | 70.0 (37-133)                     | 69.0 (38-128)                       |
| WHO performance status, n (%)  |                                    |                                     |
| 0                              | 99 (50.3)                         | 45 (50.0)                           |
| 1                              | 97 (49.2)                         | 44 (48.9)                           |
| Missing                        | 1 (0.5)                           | 1 (1.1)                             |
| Histology                      |                                    |                                     |
| Squamous                       | 88 (44.7)                         | 36 (40.0)                           |
| Non-squamous                   | 109 (55.3)                        | 54 (60.0)                           |
| AJCC disease stage             |                                    |                                     |
| IIA                            | 197 (100)                         | 90 (100)                            |
| IIIB                           | 0                                 | 0                                   |
| Other                          | 0                                 | 0                                   |
| EGFR/ALK aberration status, n (%)|                                    |                                     |
| Negative                       | 130 (66.0)                        | 63 (70.0)                           |
| Positive                       | 12 (6.1)                          | 7 (7.8)                             |
| Unknown                        | 55 (27.9)                         | 20 (22.2)                           |
| PD-L1 expression level, n (%)  |                                    |                                     |
| <25%                           | 79 (40.1)                         | 43 (47.8)                           |
| ≥25%                           | 45 (22.8)                         | 14 (15.6)                           |
| Unknown                        | 73 (37.1)                         | 33 (36.7)                           |
| Prior radiotherapy (Gy), n (%) |                                    |                                     |
| <54                            | 0                                 | 3 (1.1)                             |
| ≥54–<66                        | 180 (91.4)                        | 86 (95.6)                           |
| ≥66–<74                        | 17 (8.6)                          | 4 (4.4)                             |
| >74                            | 0                                 | 0                                   |
| Prior cytotoxic chemotherapy, n (%)|                                    |                                     |
| Adjuvant                       | 38 (19.3)                         | 19 (21.1)                           |
| Induction                      | 197 (100)                         | 90 (100)                            |
| Definitive                     | 3 (1.6)                           | 1 (1.1)                             |
| Not applicable                 | 0                                 | 0                                   |
| Prior definitive CRT chemotherapy regimen, n (%)|                                    |                                     |
| Cisplatin-based                | 103 (52.6)                        | 51 (56.7)                           |
| Carboplatin-based              | 91 (46.4)                         | 38 (42.2)                           |
| Cisplatin/carboplatin-based    | 2 (1.0)                           | 1 (1.1)                             |
| Best response to prior therapy, n (%)|                                    |                                     |
| Complete response              | 3 (1.5)                           | 1 (1.1)                             |
| Partial response               | 94 (47.7)                         | 33 (36.7)                           |
| Stable disease                 | 100 (50.8)                        | 53 (58.9)                           |
| Progressive disease            | 0                                 | 0                                   |
| Not evaluable/applicable       | 0                                 | 0                                   |
| Time from radiotherapy end to randomization, n (%)|                                    |                                     |
| <14 days                       | 45 (22.8)                         | 22 (24.4)                           |
| >14 days                       | 152 (77.2)                        | 68 (75.6)                           |

AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; CRT, chemoradiotherapy; EGFR, epidermal growth factor receptor; Gy, units of gray; NSCLC, non-small-cell lung cancer; PD-L1, programmed cell death-ligand 1; WHO, World Health Organization.

aPatients with all other stages (including stages IIIA-N0/N1 and IIIB).
bNo sample collected or no valid test result.
cBased on the definitive platinum-based chemotherapy regimen only.
dBased on the last cycle of therapy before entering the study.

(3 Table 3). Consistent with the ITT population, a higher proportion of patients experienced any-grade pneumonitis/radiation pneumonitis with durvalumab versus placebo in both subgroups [stage IIIA-N2: 72/195 (36.9%) versus 24/89 (27.0%); all others: 89/280 (31.8%) versus 34/145 (23.4%)]. Within the durvalumab arm, there were limited differences in the receipt of post-discontinuation anticancer therapy between patients with and without stage IIIA-N2 disease (Supplementary Table S2, available at https://doi.org/10.1016/j.esmoop.2022.100410). However, within the placebo arm, proportionally more patients with (versus those without) stage IIIA-N2 disease received any post-discontinuation anticancer therapy [55/90 (61.1%) versus 73/147 (49.7%)]; in particular, post-discontinuation receipt
of cytotoxic chemotherapy was higher among patients with stage IIIA-N2 disease, relative to those without.

DISCUSSION

In the PACIFIC trial, observed treatment benefits (in terms of PFS, OS, and TTDM) favored durvalumab versus placebo, with a manageable safety profile, irrespective of stage IIIA-N2 status. These findings were consistent with results for the ITT population.  

Stage IIIA-N2 NSCLC is a heterogeneous disease, with patients varying in terms of their fitness to undergo curative-intent treatment. Consequently, current treatment guidelines are somewhat complex, comprising multimodality regimens of chemotherapy with radiotherapy and/or surgical resection, with the combination and sequence of modalities tailored according to the disease characteristics of individual patients.  

Figure 1. Shown are Kaplan-Meier curves for PFS. The tick marks indicate censored data, and the dashed vertical lines indicate the times of landmark analyses of PFS. PFS in patients (A) with or (B) without* stage IIIA-N2 NSCLC.

CI, confidence interval; DCO, data cut-off; HR, hazard ratio; NE, not estimable; NR, not reached; NSCLC, non-small-cell lung cancer; PFS, progression-free survival.

*A patients with all other stages (including stages IIIA-N0/N1 and IIIB). DCO = 13 February 2017 (DCO for the primary analysis of PFS): median follow-up of 14.5 months (range: 0.2-29.9 months).
subsets (e.g. those with minimal N2 disease) compared with others (e.g. those presenting with bulky or multilevel N2 disease). Importantly, there is, currently, no uniform definition of ‘resectable N2 disease’ and definitions can differ according to local practice and expertise. At present, the relative benefit of surgery has not been established definitively, with prospective randomized trials generally showing no significant differences in OS between patients with stage IIIA-N2 disease who did and who did not undergo surgical resection as part of a multimodality regimen. However, as much of the available data were generated before the current era of minimally invasive

Figure 2. Shown are Kaplan-Meier curves for OS. The tick marks indicate censored data, and the dashed vertical lines indicate the times of landmark analyses of OS.

OS in patients (A) with or (B) without* stage IIIA-N2 NSCLC.

CI, confidence interval; DCO, data cut-off; HR, hazard ratio; NE, not estimable; NR, not reached; NSCLC, non-small-cell lung cancer; OS, overall survival.

*Patients with all other stages (including stages IIIA-N0/N1 and IIIB). DCO = 22 March 2018 (DCO for the primary analysis of OS): median follow-up of 25.2 months (range: 0.2 - 43.1 months).
staging procedures/surgical resections and modern radiotherapy techniques (enabling improved tissue sparing), and as some key studies did not mandate histological confirmation of N2 disease, results of these older studies may not reflect the potential survival benefit in suitable subsets of patients with stage IIIA-N2 disease.

The findings of the present study (albeit carried out in patients with unresectable disease) emphasize the need to better define operability in the stage IIIA-N2 disease setting in order to demarcate patients who are more likely to benefit from surgery following chemotheraphy/CRT. Future studies should seek to assess the impact of the PACIFIC regimen on progression patterns in patients with stage IIIA-N2 disease, as this information will help inform discussions regarding the optimum multimodal treatment approach for patients (given that surgery is expected to improve locoregional control). We did not analyze locoregional failure for the present study as radiotherapy planning parameters were not collected as part of the PACIFIC protocol. This is an important limitation of the study as it was not possible to correlate disease progression with prior radiation fields in all cases.

The treatment landscape for patients with resectable NSCLC is evolving rapidly. Recently, the US Food and Drug Administration approved use of adjuvant (anti-PD-L1) immunotherapy following resection and platinum-based chemotherapy for patients with stage II-IIIA NSCLC (and whose tumors have PD-L1 expression on ≥1% of tumor cells). In addition, several ongoing phase III trials are assessing neoadjuvant chemotherapy followed by surgery (e.g. NCT03800134, NCT02998528, and NCT03425643). The utility of immunotherapy in patients with stage II-IIIA NSCLC, including in patients who are deemed resectable (either in combination with or instead of surgery), remains unclear. Multiple early-phase clinical trials are evaluating neoadjuvant/adjuvant immunotherapy in patients with resectable, stage II-IIIA NSCLC. For example, data from a single-arm phase II study demonstrated a 1-year event-free survival rate of 73% (90% CI 63-82) with neoadjuvant/adjuvant durvalumab in this setting. However, larger comparative trials of surgical and non-surgical strategies for these patients are warranted.

The analyses reported in the present study are limited by their post hoc, exploratory nature. The PACIFIC trial was not designed to assess clinical outcomes with durvalumab according to specific disease stage, and complete details of mediastinal lymph node site involvement and gross tumor volumes were unavailable. In addition, details underlying the decision to deem each patient unresectable were not collected (with decision making at the discretion of the local institutions).

### Table 2. TTDM and ORR in patients with or without stage IIIA-N2 NSCLC

| TTDM events, n (%) | Durvalumab (n = 197) | Placebo (n = 90) | Durvalumab (n = 279) | Placebo (n = 147) |
|-------------------|---------------------|----------------|---------------------|------------------|
| TTDMD HR (95 CI)  | 0.45 (0.30-0.69)     | 0.63 (0.45-0.88) | 0.45 (0.30-0.69)     | 0.63 (0.45-0.88)   |
| PFS, months       | 12.6 (8.7-25.9)      | 23.2 (17.8-NE)  | 12.6 (8.7-25.9)      | 23.2 (17.8-NE)     |
| ORR, n/N (%)      | 62/185 (33.5)        | 64/258 (24.8)   | 62/185 (33.5)        | 64/258 (24.8)     |
| [95% CI]          | [26.8-40.8]          | [19.7-30.5]     | [26.8-40.8]          | [19.7-30.5]        |

**Table 3. Safety profile for patients with or without stage IIIA-N2 NSCLC**

| Any-grade all-causality AEs, n (%) | Durvalumab (n = 195) | Placebo (n = 89) | Durvalumab (n = 280) | Placebo (n = 145) |
|-----------------------------------|---------------------|----------------|---------------------|------------------|
| Any-grade pneumonitis/radiation pneumonitisa, n (%) | 72 (36.9) | 89 (31.8) | 72 (36.9) | 89 (31.8) |
| Grade 1                           | 21 (10.8) | 11 (12.4) | 21 (10.8) | 11 (12.4) |
| Grade 2                           | 39 (20.0) | 7 (7.9) | 39 (20.0) | 7 (7.9) |
| Grade 3                           | 10 (5.1) | 7 (2.5) | 10 (5.1) | 7 (2.5) |
| Grade 4                           | 0 | 0 | 0 | 0 |
| Grade 5                           | 2 (1.0) | 3 (1.1) | 2 (1.0) | 3 (1.1) |

**DCO** = 22 March 2018 (DCO for the primary analysis of OS); median follow-up of 25.2 months (range: 0.2-43.1 months). AE, adverse event; DCO, data cut-off; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PFS, progression-free survival; TTDM, time to death or distant metastasis.

aPatients with all other stages (including stages IIIA-N0/N1 and IIIB).

b Patients with stage IIIA-N2 NSCLC.

cORR for response-assessable patients includes unconfirmed responses (N; response-assessable population).

pORR 95% CI were calculated using the Clopper–Pearson method.
principal investigator and associated multidisciplinary team), and study enrollment was not stratified according to TNM (tumor—node—metastasis) classification. Therefore, while clinical benefit with durvalumab (versus placebo) was observed irrespective of stage IIIA-N2 status, robust conclusions cannot be drawn due to the inherent lack of sufficient statistical power and imbalances in potentially prognostic baseline factors.

Conclusions

In the PACIFIC trial, treatment benefit was observed with durvalumab versus placebo in patients with stage IIIA-N2, unresectable NSCLC. In the era of immune checkpoint inhibitors, prospective clinical studies comparing surgical and non-surgical strategies are warranted to establish the optimal treatment approach for patients with stage IIIA-N2 NSCLC who are potentially operable. Furthermore, improved and uniform definitions of patients who may or may not be suitable for surgery will be essential in this setting.

ACKNOWLEDGEMENTS

Medical writing support, under the direction of the authors, was provided by James Holland, PhD, of Ashfield MedComms (Macclesfield, UK), an Ashfield Health company, and was funded by AstraZeneca. CF-F is supported by a grant from the National Institute for Health Research (NIHR) Manchester Biomedical Research Center.

FUNDING

This study (NCT02125461) was sponsored by AstraZeneca (no grant number).

DISCLOSURE

SS reports participating on advisory boards for AstraZeneca, Celgene, Merck Sharp & Dohme, BeiGene, Eli Lilly, and Varian Medical Systems; and institutional research grants from AstraZeneca, Varian Medical Systems, and ViewRay Inc. MÖ reports receiving personal fees from Janssen, Astellas, Bristol-Myers Squibb, Novartis, Pfizer, Roche, Sanofi, AstraZeneca, and MSD; and reports receiving a research grant from Janssen. DD reports receiving institutional research support from AstraZeneca, Genentech, Guardant Health, Janssen Research and Development, Bristol-Myers Squibb, G1 Therapeutics, Merck & Co, Inc., Novartis, AbbVie, ARMO Biosciences, Immunomedics, Eli Lilly, Merus NV, and Daiichi Sankyo. AV reports receiving personal fees for participating in a speakers’ bureau for AstraZeneca. DV reports receiving honoraria from AstraZeneca; receiving institutional research support from AstraZeneca, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, and Roche; undertaking a consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MDS Oncology, Pfizer, and Roche/Genentech; and receiving travel/accommodation/expenses from AstraZeneca, Pfizer, Merck Sharp & Dohme, and Roche. SM reports receiving institutional research support from Takeda Pharmaceuticals; and receiving travel/accommodations/expenses from AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, Tailho Pharmaceutical, and Ono Pharmaceutical. RH reports participating on advisory boards for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Oncosec, Pfizer, Seagen, and Roche; receiving honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Oncosec, Pfizer, Seagen, and Roche; receiving research funding (paid to the institution) from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Novartis, Oncosec, Roche, and Seagen; and receiving travel, accommodations, and expenses from Novartis. CF-F reports receiving honoraria from AstraZeneca; participating in a speaker’s bureau and an advisory board for AstraZeneca (fees paid to institution); is a scientific committee member/chair for AstraZeneca; and reports receiving research funding and travel, accommodations, or expenses from AstraZeneca and Elekta. LP-A reports being board member of Genomica; participating in a leadership role for ALTUM Sequencing; participating in a speaker’s bureau for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merk Serono, MSD Oncology, Pfizer, and Roche/Gentech; receiving honoraria from Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Incyte, Ipsen, Eli Lilly, Merck Serono, Mirati Therapeutics, MSD, Novartis, Pfizer, PharmaMar, Roche/Gentech, Sanofi, Servier, Sysmex, and Takeda; receiving research funding (paid to the institution) from AstraZeneca, Bristol-Myers Squibb, Kura Oncology, Merck Sharp and Dohme, and PharmaMar; and receiving travel, accommodations, or expenses from Roche, AstraZeneca, AstraZeneca Spain, Bristol-Myers Squibb, Merck Sharp and Dohme, Eli Lilly, Pfizer, and Takeda. YLW reports receiving institutional research support from Roche, Pfizer, and Boehringer Ingelheim; receiving consultancy fees from AstraZeneca, Boehringer Ingelheim, Takeda, Roche, and Merck; and receiving honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/China, Hengrui Pharmaceutical, MSD Oncology, Eli Lilly, Roche, Pierre Fabre, Pfizer, Sanofi, and Merck. HM is an employee of AstraZeneca and holds stock or stock options in AstraZeneca. PAD is a former employee of AstraZeneca and holds stock or stock options in AstraZeneca. SJA reports a consulting or advisory role for AstraZeneca, Achilles Therapeutics, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, CBMG, Celsius Therapeutics, EMD Serono, G1 Therapeutics, GlaxoSmithKline, Glymapse Bio, Memgen, Merck, RAPT Therapeutics, Samyang, Tarus Therapeutics, and Venn Therapeutics.

REFERENCES

1. European Medicines Agency. Durvalumab (Imfinzi). Summary of product characteristics 2021. 2021. Available at https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Accessed August 25, 2021.

2. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.

https://doi.org/10.1016/j.esmoop.2022.100410
3. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
4. Hui R, Ozguroglu M, Villegas A, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unselectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(12):1670-1680.
5. Evison M, Clive A, Castle L, et al. Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. J Thorac Oncol. 2017;12(9):1434-1441.
6. van Schil PE, Yogeswaran K, Hendriks JM, Lauwers P, Faivre-Finn C. Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer. Expert Rev Anticancer Ther. 2017;17(6):555-561.
7. ESMO Guidelines Committee — European Medicines Agency. eUpdate — Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) Treatment Recommendations; May 4, 2020. 2020. Available at https://www.esmo.org/guidelines/lung-and-chest-tumours/early-stage-and-locally-advanced-non-metastatic-non-small-cell-lung-cancer-eupdate-early-and-locally-advanced-non-small-cell-lung-cancer-nsclc-treatment-recommendations. Accessed August 25, 2021.
8. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21.
9. Spicer JD, Shewale JB, Nelson DB, et al. Multimodality therapy for N2 non-small cell lung cancer: an evolving paradigm. Ann Thorac Surg. 2019;107(1):277-284.
10. van Schil PE. Optimal treatment of stage IIIA-N2 non-small cell lung cancer: a neverending story? J Thorac Oncol. 2017;12(9):1338-1340.
11. Eberhardt WE, De Ruyscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26(8):1573-1588.
12. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379-386.
13. Eberhardt WE, Pottgen C, Gauer TC, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATEUE). J Clin Oncol. 2015;33(35):4194-4201.
14. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54(2):365-369.
15. Nardone V, Correale P, Guida C. The optimal choice of local therapy for stage IIIA-N2 NSCLC: is radiotherapy inferior to surgery? Ann Thorac Surg. 2019;108(3):961-962.
16. Stephens RJ, Girling DJ, Hopwood P, Thatcher N. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer. Lung Cancer. 2005;49(3):395-400.
17. van Meerbeeck JP, Kramer GW, van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442-450.
18. Zhao Y, Wang W, Liang H, et al. The optimal treatment for stage IIIA-N2 non-small cell lung cancer: a network meta-analysis. Ann Thorac Surg. 2019;107(6):1866-1875.
19. Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol. 2016;11(1):115.
20. Christodoulou M, Bayman N, McColskey P, Rowbottom C, Faivre-Finn C. New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J Cancer. 2014;50(3):525-534.
21. US Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. 2021. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Accessed November 19, 2021.
22. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(11):1413-1422.
23. Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: Durvalumab in resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATEUE). J Clin Oncol. 2015;33(35):4194-4201.